Cagrilintide is a long-acting amylin analogue that reduces appetite through the amylin and calcitonin receptors
Across these, the common message was that muscle-first formulation, not appetite suppression, is where companion products add value
For many patients, this translates to nausea, particularly in the early weeks of treatment or when doses are increased
On todays episode, we break down the science behind Retatrutide, a new GLP-1based peptide being compared to Ozempic for its potential to drive even greater weight loss
Added to this is a theoretical tumor-growth concern, reflected in the labeled warnings of approved GHRH analogs such as tesamorelin, since IGF-1 represents a growth signal for existing cell populations
Preliminary work with previously sedentary subjects failed to indicate performance effects related to VO2max assessed via graded exercise treadmill testing or anaerobic energy assessed via a 30-second cycle sprint